scholarly journals CytoPAN—Portable cellular analyses for rapid point-of-care cancer diagnosis

2020 ◽  
Vol 12 (555) ◽  
pp. eaaz9746
Author(s):  
Jouha Min ◽  
Lip Ket Chin ◽  
Juhyun Oh ◽  
Christian Landeros ◽  
Claudio Vinegoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Point Of Care ◽  
Growth Factor Receptor ◽  
Image Cytometry ◽  
Breast Cancer Diagnosis ◽  
Needle Aspiration ◽  
Current Standard ◽  
Diagnose Breast Cancer ◽  
Palpable Mass

Rapid, automated, point-of-care cellular diagnosis of cancer remains difficult in remote settings due to lack of specialists and medical infrastructure. To address the need for same-day diagnosis, we developed an automated image cytometry system (CytoPAN) that allows rapid breast cancer diagnosis of scant cellular specimens obtained by fine needle aspiration (FNA) of palpable mass lesions. The system is devoid of moving parts for stable operations, harnesses optimized antibody kits for multiplexed analysis, and offers a user-friendly interface with automated analysis for rapid diagnoses. Through extensive optimization and validation using cell lines and mouse models, we established breast cancer diagnosis and receptor subtyping in 1 hour using as few as 50 harvested cells. In a prospective patient cohort study (n = 68), we showed that the diagnostic accuracy was 100% for cancer detection and the receptor subtyping accuracy was 96% for human epidermal growth factor receptor 2 and 93% for hormonal receptors (ER/PR), two key biomarkers associated with breast cancer. A combination of FNA and CytoPAN offers faster, less invasive cancer diagnoses than the current standard (core biopsy and histopathology). This approach should enable the ability to more rapidly diagnose breast cancer in global and remote settings.

Breast Cancer Diagnosis With Mammography

2021 ◽  
pp. 107-127
Author(s):  
Abir Baâzaoui ◽  
Walid Barhoumi
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Gold Standard ◽  
Breast Cancer Diagnosis ◽  
Black Box ◽  
Diagnose Breast Cancer ◽  
Cad Systems ◽  
Helpful Tool ◽  
Cancerous Lesion ◽  
Aided Diagnosis

Breast cancer, which is the second-most common and leading cause of cancer death among women, has witnessed growing interest in the two last decades. Fortunately, its early detection is the most effective way to detect and diagnose breast cancer. Although mammography is the gold standard for screening, its difficult interpretation leads to an increase in missed cancers and misinterpreted non-cancerous lesion rates. Therefore, computer-aided diagnosis (CAD) systems can be a great helpful tool for assisting radiologists in mammogram interpretation. Nonetheless, these systems are limited by their black-box outputs, which decreases the radiologists' confidence. To circumvent this limit, content-based mammogram retrieval (CBMR) is used as an alternative to traditional CAD systems. Herein, authors systematically review the state-of-the-art on mammography-based breast cancer CAD methods, while focusing on recent advances in CBMR methods. In order to have a complete review, mammography imaging principles and its correlation with breast anatomy are also discussed.

scholarly journals Evaluation of the Reconfiguration of the Data Acquisition System for 3D USCT

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Matthias Birk ◽  
Clemens Hagner ◽  
Matthias Balzer ◽  
Nicole V. Ruiter ◽  
Michael Hübner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Data Acquisition ◽  
Cancer Diagnosis ◽  
Three Dimensional ◽  
Breast Cancer Diagnosis ◽  
Data Acquisition System ◽  
Screening Methods ◽  
Diagnose Breast Cancer ◽  
Bidirectional Communication ◽  
Existing Data

As today's standard screening methods often fail to diagnose breast cancer before metastases have developed, an earlier breast cancer diagnosis is still a major challenge. To improve this situation, we are currently developing a fully three-dimensional ultrasound computer tomography (3D USCT) system, promising high-quality volume images of the breast. For obtaining these images, a time-consuming reconstruction has to be performed. As this is currently done on a PC, parallel processing in reconfigurable hardware could accelerate both signal and image processing. In this work, we investigated the suitability of an existing data acquisition (DAQ) system for further computation tasks. The reconfiguration features of the embedded FPGAs have been exploited to enhance the systems functionality. We have adapted the DAQ system to allow for bidirectional communication and to provide an overall process control. Our results show that the studied system can be applied for data processing.

Breast Cancer Diagnosis by Fine Needle Aspiration and Excisional Biopsy

1997 ◽  
Vol 41 (2) ◽  
pp. 302-306 ◽  
Author(s):  
Amy Taxin ◽  
Paul Ian Tartter ◽  
Dana Zappetti
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Fine Needle Aspiration ◽  
Breast Cancer Diagnosis ◽  
Excisional Biopsy ◽  
Needle Aspiration ◽  
Fine Needle

scholarly journals Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy Users

2010 ◽  
Vol 70 (21) ◽  
pp. 8598-8606 ◽  
Author(s):  
Sharon J. Pitteri ◽  
Lynn M. Amon ◽  
Tina Busald Buson ◽  
Yuzheng Zhang ◽  
Melissa M. Johnson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Diagnosis ◽  
Plasma Levels ◽  
Growth Factor Receptor ◽  
Breast Cancer Diagnosis ◽  
Elevated Plasma ◽  
Epidermal Growth

Impact of updated 2013 human epidermal growth factor receptor-2 testing guidelines on HER2 positive invasive breast cancer diagnosis: A three year retrospective study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12554-e12554
Author(s):  
Hemendra Mhadgut ◽  
Purva Sharma ◽  
Fady Tawadros ◽  
Bill Brooks ◽  
Anna Yakubenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Cancer Diagnosis ◽  
Growth Factor Receptor ◽  
Kappa Statistic ◽  
Breast Cancer Diagnosis ◽  
Her2 Positive ◽  
Epidermal Growth ◽  
New Criteria

e12554 Background: Breast cancer is a frequently diagnosed malignancy in the United States accounting for approximately 266,000 cases and 40,000 deaths annually. Human epidermal growth factor receptor 2 (HER2) is a surface protein shown to affect cell proliferation, migration and survival - the hallmarks of neoplastic cells. HER2 is overexpressed in 20-35% of breast cancer cases and has a strong prognostic and therapeutic significance. This discovery led to development of therapeutic agents targeting HER 2 receptor. In 2013, College of American Pathologists (CAP) updated their recommendations for HER2 testing by incorporating an algorithm with immunohistochemistry (IHC) and In situ hybridization (ISH). The primary objective of our study was to assess for variance in HER2 interpretation by applying the updated 2013 criteria to all diagnosed cases in our hospital for the immediate previous three years. Methods: We retrospectively reviewed charts of patients diagnosed with invasive breast carcinoma from January 1, 2010 to December 31, 2012 at our hospital. The new American college of pathology criteria assessing FISH HER2 copy number and HER2/CEP ratio for each patient was compared to the old criteria to assess for variance in HER2 interpretation. Categorical variables are presented as percentages and kappa statistic was used to assess for variance. Results: We reviewed 526 charts with an invasive breast cancer diagnosis over a 3-year period. 10.83% of patients were HER2 amplified, 86.12% were non-amplified and 3.04% were equivocal. Applying the updated 2013 CAP criteria, we found that 11.21% were amplified, 74.33% were non amplified, and 14.44% remained equivocal. Kappa statistic indicated substantial agreement (0.804) between the old and new criteria. A review of our cohort revealed an overall lower level of HER2 positive cases at 10.83% (old criteria) and 11.21% (updated criteria) when compared to historical studies. The increase in equivocal cases from 3.04% to 14.44% with the new criteria suggests under diagnosis of HER2 positive cases. Due to the lack of IHC performed (as per old standards), further classification of equivocal cases (based on new criteria) was not possible. While we saw some movement in our data from non-amplified to equivocal, our analysis indicated substantial statistical agreement between the old and the new diagnostic criteria Conclusions: Our study did not show a variance in HER2 interpretation between the 2007 and 2013 CAP criteria which is reassuring. An increase of 11.4% cases in the equivocal category was noted and may reveal a significant difference if further delineation is feasible. This variance could be important given the prognostic and therapeutic implications in HER2 positive breast cancer.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document